The in vivo study of HNSCC mouse model showed that the A2AR antagonist, SCH58261, not only delayed the tumor growth but also significantly reduced the population of CD4+ Foxp3+ Tregs and increased the anti-tumor response of CD8+ T cells in HNSCC tumors (137). This evidence concerns the gene FOXP3 and neoplasm.